This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus Therapeutics Announces Posters And Presentations At Society For The Study Of Inborn Errors Of Metabolism Symposium 2012

CRANBURY, N.J., Aug. 27, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that 1 presentation and 4 posters related to its investigational pharmacological chaperones will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2012. SSIEM 2012 will be held September 4-7, 2012 in Birmingham, United Kingdom.

An Ongoing Phase 2a Study to Investigate the Effects of AT2220 (duvoglustat HCl) on the Pharmacokinetics of Acid Alpha-Glucosidase in Subjects with Pompe Disease - Preliminary Results. - Kishnani P., Tarnopolsky M., Sivakumar K., Byrne B., Goker-Alpan O., Guter K., Pervaiz M., Dasouki M., Levine T., Roberts M., Johnson F., Sitaraman S., Winkler R., Khanna R., Flanagan J., Sjoberg E., Valenzano K., Lockhart D., Boudes P.
  • Poster: September 5, 2012, 17:30 – 19:30 BST; September 6, 2012 12:00 -13:00 BST

A Novel Phase 2a Study Design to Investigate the Effect of AT2220 (duvoglustat HCl) on the Pharmacokinetics of Acid Alpha-Glucosidase in Subjects with Pompe Disease. – Kishnani P., Tarnopolsky M., Sivakumar K., Byrne B., Goker-Alpan O., Guter K., Pervaiz M., Dasouki M., Levine T., Roberts M., Johnson F., Winkler R., Valenzano K., Lockhart D., Boudes P.
  • Poster: September 5, 2012, 17:30 – 19:30 BST; September 6, 2012 12:00 -13:00 BST

The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid Alpha-Glucosidase Tissue Uptake and Improves Glycogen Reduction in a Mouse Model of Pompe Disease. – Pellegrino L., Feng J., Frascella M., Lun Y., Flanagan J., Guillen D., Benjamin E., Lockhart D., Valenzano K., Khanna R.
  • Poster: September 5, 2012, 17:30 – 19:30 BST; September 6, 2012 12:00 -13:00 BST

Migalastat HCl, an Investigational Pharmacological Chaperone Therapy: Screening Results from FACETS, a Phase 3 Study in Male and Female Fabry Patients. – Nicholls, K., Castelli J., Winkler, Sitaraman, S., Benjamin E., Wu, X., Duke C., Boudes, P., on Behalf of FACETS Study AT1001-011 Principal Investigators.
  • Poster: September 5, 2012, 17:30 – 19:30 BST; September 6, 2012 12:00 -13:00 BST

Migalastat HCl Reduces Globtriaosylsphingosine (Lyso-GB3) in Plasma of Fabry Patients and in Tissues of Fabry Transgenic Mice. – Benjamin E., Brignol N., Young B., Chang H., Khanna R., Soska R., Sitaraman S., Germain D., Giugliani R., Hughes D., Mehta A., Nicholls K., Boudes P., Lockhart D., Valenzano K.
  • Presentation: September 6, 2012, 13:00 – 14:30 BST

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs